Adrenoceptor Subtype Affinity
Adrenoceptor Subtype Affinity - Related Videos
14:40
Expression Analysis of Mammalian Linker-histone Subtypes
0 Views •
Cited by 22 •
2012
We describe a set of assays to analyze expression levels of H1 linker histones. mRNA of individual H1 genes are quantitatively measured by random primer based reverse transcription followed by real-time PCR, whereas protein quantification of H1 histones is achieved by HPLC analysis.
03:07
Electron Affinity
0 Views •
2020
The electron affinity (EA) is the energy change for adding an electron to a gaseous atom to form an anion (negative ion). This process can be either endothermic or exothermic, depending on the element. Many of these elements have negative values of EA, which means that energy is released when the gaseous atom accepts an electron. However, for some elements, energy is required for the atom to become negatively charged, and the value of their EA is positive. Just as with ionization energy,...
01:41
Affinity and Avidity
0 Views •
2019
Overview Antibodies bind to toxins or substances on the surface of cells, bacteria, viruses, or fungi. The substance is called an antigen, and the precise binding site is the epitope. The strength of the antibody-epitope interaction is called affinity. When an antibody binds an antigen by multiple epitopes, the cumulative strength of the interaction is called avidity. The strength of the interaction influences the elicited immune response. The Adaptive Immune System Increases Efficiency by...
01:27
Adrenergic Receptors (Adrenoceptors): Classification
0 Views •
2023
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists. α-Adrenoceptors α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
06:42
Subtype-selective Electroporation of Cortical Interneurons
0 Views •
Cited by 13 •
2014
This procedure shows how to target interneurons in the developing mouse forebrain by means of in utero electroporation. This technique was particularly efficient to achieve selective gene expression in interneuron subtypes destined to the superficial layers of the cortex.
FAQs
The strength of binding depends on how a ligand interacts with the binding site of a particular adrenergic receptor. Differences in these molecular interactions can produce stronger or weaker binding across α1, α2, β1, β2, and β3 subtypes. Comparing those relationships helps explain why the same ligand may produce different pharmacological effects through different receptor populations.
Selectivity reflects differences in affinity among receptor subtypes, but those differences do not remain equally important at every concentration. As drug concentration changes, receptors with lower relative affinity may also become engaged. Consequently, a compound that appears subtype-preferential under one condition can produce a broader receptor response under another, affecting both desired and unwanted pharmacological effects.
Affinity describes the tendency to bind a receptor, whereas potency concerns the amount of drug needed to produce an effect. Agonist or antagonist activity describes what occurs after receptor interaction. These properties are related but not interchangeable: a ligand may bind strongly, yet its observed pharmacological outcome also depends on whether it activates or blocks the receptor and how tissue responses are measured.
These subtype categories provide a framework for linking ligand binding patterns with responses in different adrenergic systems. Examining them separately can reveal whether an effect is associated primarily with one receptor group or with activity across several groups. That comparison supports interpretation of tissue responses rather than treating adrenergic signaling as a single uniform process.
A study can compare how strongly a drug or endogenous ligand binds to the relevant adrenergic receptor subtypes, then examine the resulting differences in affinity. Researchers can relate those comparisons to agonist or antagonist activity, potency, and tissue responses. This workflow connects receptor-level binding information with the broader pharmacological behavior of the ligand.
Subtype affinity information is useful when designing or interpreting drugs intended to influence cardiovascular, respiratory, neurological, or metabolic functions. Comparing binding across receptor subtypes can help identify a preferred pharmacological target and anticipate activity at other receptors. That knowledge supports efforts to preserve intended effects while limiting responses associated with unwanted subtype engagement.
Tissue responses can differ when a ligand interacts with distinct adrenergic receptor subtypes and produces different patterns of agonist or antagonist activity. Evaluating affinity alongside potency and observed responses helps connect receptor binding to functional outcomes. In pharmacology, this comparison provides a basis for interpreting why one compound may produce different effects across cardiovascular, respiratory, neurological, or metabolic settings.